Wee Joo Chng

Chng Wee Joo

Appointment(s)
  • Professor, Department of Medicine
  • Senior Consultant, Division of Haematology, Department of Haematology-Oncology, National University Cancer Institute, Singapore, National University Health System
Administrative Appointment(s)
  • Director, National University Cancer Institute, Singapore, National University Health System
  • Head, Division of Haematology, Department of Haematology-Oncology, National University Cancer Institute, National University Health System
  • Deputy Director, Cancer Science Institute of Singapore, National University of Singapore
  • Leader, Haematologic Malignancy Tumour Group, National University Cancer Institute, Singapore, National University Health System
  • Lead, Cancer Summit Research Programme, National University Health System
Academic Qualifications
  • PhD,¬†National University of Singapore, Singapore
  • MBChB, University of Leeds, United Kingdom
  • FRCP, Royal College of Edinburgh, United Kingdom¬†| FRCPath, Royal College of Pathologists, United Kingdom
  • FAMS, Academy of Medicine, Singapore
Research Interest(s)
  • Myeloma
  • Genetics
  • Clinical Trials
  • Leukaemia
  • Lymphoma
  • Haematologic Malignancies
Recent Publications
  • 1. Laubach J, Garderet L, Mahindra A, Gahrton G, Caers J, Sezer O, Voorhees P, Leleu X, Johnsen HE, Streetly M, Jurczyszyn A, Ludwig H, Mellqvist UH, Chng WJ, Pilarski L, Einsele H, Hou J, Turesson I, Zamagni E, Chim CS, Mazumder A, Westin J, Lu J, Reiman T, Kristinsson S, Joshua D, Roussel M, O'Gorman P, Terpos E, McCarthy P, Dimopoulos M, Moreau P, Orlowski RZ, Miguel JS, Anderson KC, Palumbo A, Kumar S, Rajkumar V, Durie B, Richardson PG. 2016 May. Management of relapsed multiple myeloma: Recommendations of the International Myeloma Working Group. Leukemia. 30(5):1005-17. doi: 10.1038/leu.2015.356. 26710887.
  • 2. Chng WJ, Chung TH, Kumar S, Usmani S, Munshi N, Avet-Loiseau H, Goldschmidt H, Durie B, Sonneveld P. 2016 May. Gene signature combinations improve prognostic stratification of multiple myeloma patients. Leukemia. 30(5):1071-8. doi: 10.1038/leu.2015.341. 26669975.
  • 3. Xie Z, Bi C, Chooi JY, Chan ZL, Mustafa N, Chng WJ. 2015 Dec. MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib. Leukemia. 29(12):2347-54. doi: 10.1038/leu.2015.169. 26196464.
  • 4. Garg M, Nagata Y, Kanojia D, Mayakonda A, Yoshida K, Haridas Keloth S, Zang ZJ, Okuno Y, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Ding LW, Alpermann T, Sun QY, Lin DC, Chien W, Madan V, Liu LZ, Tan KT, Sampath A, Venkatesan S, Inokuchi K, Wakita S, Yamaguchi H, Chng WJ, Kham SK, Yeoh AE, Sanada M, Schiller J, Kreuzer KA, Kornblau SM, Kantarjian HM, Haferlach T, Lill M, Kuo MC, Shih LY, Blau IW, Blau O, Yang H, Ogawa S, Koeffler HP. 2015 Nov. Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse. Blood. 126(22):2491-501. doi: 10.1182/blood-2015-05-646240. 26438511.
  • 5. Li XL, Zhou J, Chan ZL, Chooi JY, Chen ZR, Chng WJ. 2015 Nov. PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms. Oncotarget. 6(34):36689-99. doi: 10.18632/oncotarget.5385. 26452133.